Contemporary aspects of the diagnostics and conservative treatment of the lower urinary tract symptoms caused by BPH

Abstract

Lower urinary tract symptoms (LUTS) are referred to a group of medical symptoms that affect approximately 40% of men of older age and significantly affect their quality of life. Benign prostatic hyperplasia (BPH) is known to be the main cause of LUTS. Clinical manifestations caused by BPH are observed in 10% of men in the age group under 40 years old and in 40–61% of men under 70 years old. The objective of our study was to evaluate the efficacy and safety of Tamsulosin (Omnik, Astelas) in patients with LUTS caused by BPH. The study included 39 patients with LUTS against the background of BPH. The mean age of patients was 65.2±4.2 y. The criterion for inclusion into the study was the diagnosis of BPH, established on the basis of clinical symptoms, anamnesis, physical examination, the results of questionnaire by IPSS scale, quality of life index QoL, urinalysis, PSA, prostate and urinary tract ultrasound findings with determination of
the residual urine volume after urination, uroflowmetry data LUTS severity had decreased in the majority of patients following treatment with Omnik in dosage of 0.4 mg daily for 12 weeks. We have obtained statistically significant changes in the scores on the IPSS scale (International Prostate Symptom Score): prior to treatment 19.8±3.2 points, and at 12th week after treatment – 10.5±2.7 points. Changes in the maximum urine flow rate Qmax under the treatment demonstrated high efficiency of Omnik (before treatment – 6.6 ml/s, at the 4th week after treatment – 8.3 ml/s and at 12th week after treatment – 10.1 ml/s). There was a direct correlation between the effectiveness of LUTS treatment and duration of Tamsulosin administration. At that adverse effects occurred were rare, mild and did not require discontinuation of treatment or specific treatment.